Cargando…
Clinical Outcomes of Patient Subgroups in the TANGO II Study
INTRODUCTION: Meropenem–vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited app...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872113/ https://www.ncbi.nlm.nih.gov/pubmed/33565042 http://dx.doi.org/10.1007/s40121-021-00405-x |